AG1®, a multi-ingredient nutrition supplement, does not negatively impact blood safety biomarkers in healthy adults: a randomized controlled trial

Background In a multistage series of experiments designed to assess the efficacy of AG1® supplementation, we performed a randomized controlled clinical trial to assess the effects of daily AG1 consumption on clinical blood safety parameters in healthy adults over 12 weeks.Methods A randomized, triple-blind, placebo-controlled parallel clinical trial was conducted in 120 healthy adults (41 ± 10 years). Participants agreed to maintain their usual diet for the entire study (assessed by ASA24®). Participants were randomly assigned to consume AG1 powder (13 g) or a placebo powder (maltodextrin, matched for appearance and taste) mixed in 8 oz of water for 12 weeks. Fasting blood samples were collected at baseline (PRE) and following 12 weeks of daily supplementation (POST) of their assigned treatment to assess markers of renal, hepatic, metabolic, and overall health [Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP), lipid panel, clinical hematological markers]. Self-reported adverse events were also monitored to assess the incidence rates of other potential side effects.Results Of the participants randomized, 105 adults completed PRE and POST blood testing (41 ± 10 years; n = 28 males). There were no significant differences in the participants’ dietary intake outside of the assigned treatments. Two-way (treatment group × time) ANCOVAs revealed no significant (p > 0.05) effects on any clinical blood safety markers with no adverse events reported for either treatment.Conclusions AG1® consumption over 12 weeks did not adversely affect renal, hepatic, or other safety markers in healthy adults. Additionally, no adverse events were reported.